Newborn Metabolic and Critical Congenital Screening

Newborn screening looks for serious, treatable conditions before an infant develops obvious symptoms. The two screening pathways measure different signals. The metabolic screen uses a dried blood spot to detect biochemical patterns associated with inherited metabolic disorders, endocrine disorders, hemoglobinopathies, cystic fibrosis, severe combined immune deficiency, spinal muscular atrophy, and other rare treatable conditions. The critical congenital heart disease (CCHD) screen uses oxygen saturation to identify infants whose circulation may not be delivering oxygen normally because of a serious cardiac lesion. Neither screen is a diagnosis. A screen-positive result means that the infant crossed a laboratory or clinical threshold and needs further assessment. It does not prove disease. Conversely, a screen-negative result lowers risk but does not replace a physical examination or explain symptoms that are already present. Timing matters because the newborn’s circulation, feeding pattern, hormone levels, and metabolism are changing rapidly after birth. Collecting or interpreting a test outside the recommended window can reduce its ability to identify disease. An infant who appears well may still have a condition detected only through screening; an infant who appears unwell...